This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: City University of Hong Kong, Hong Kong Centre for Cerebro-Cardiovascular Health Engineering Limited. Active years: 2024-2026.
Company Filing History:
2 out of 907 
1 out of 5 Years Active: 2024-2026
Title: Haojun Hua: Innovator in Liquid Biopsy Technology
Introduction
Haojun Hua is a prominent inventor based in Hong Kong, CN. He has made significant contributions to the field of medical technology, particularly in the area of liquid biopsy. His innovative work focuses on developing methods for predicting disease prognosis, which can greatly enhance patient care and treatment outcomes.
Latest Patents
Haojun Hua holds a patent for a "Label-free liquid biopsy-based disease model, analytical platform and method for predicting disease prognosis." This patent presents a platform and method that utilizes label-free liquid biopsy to establish an in vitro disease model on a microfluidic device. The invention incorporates a trained deep learning neural network that automatically extracts morphological features from cell clusters formed by the label-free liquid biopsy of a test subject. This technology aims to predict different disease stages and evaluate the efficacy of corresponding treatment regimes for the test subject. The method also includes training the neural network based on various cell cluster datasets obtained from the disease model.
Career Highlights
Haojun Hua is affiliated with the City University of Hong Kong, where he continues to advance his research and innovation in the medical field. His work has the potential to revolutionize how diseases are diagnosed and treated, making significant strides in personalized medicine.
Collaborations
Haojun has collaborated with notable colleagues, including Bee Luan Khoo and Wei Li. Their combined expertise contributes to the advancement of research in liquid biopsy technologies.
Conclusion
Haojun Hua is a key figure in the development of innovative medical technologies that leverage liquid biopsy for disease prognosis. His contributions are paving the way for more effective and personalized treatment options for patients.